Pharmacological chaperone action on G-protein-coupled receptors

Current Opinion in Pharmacology

Volumn 4, Issue 5, 2004, Pages 528-533

  Bernier, Virginie ^a,b   Bichet, Daniel G ^a,b   Bouvier, Michel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 11 CIS RETINAL; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ALITRETINOIN; BREMAZOCINE; BUPRENORPHINE; ERYTHROMYCIN; G PROTEIN COUPLED RECEPTOR; INDOLE DERIVATIVE; LIXIVAPTAN; MACROLIDE; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; NALBUPHINE; NALOXONE; NALTREXONE; NALTRIBEN; NALTRINDOLE; QUINOLONE DERIVATIVE; RELCOVAPTAN; RETINAL; TONAZOCINE;

ARTICLE; CELL MEMBRANE; ENDOPLASMIC RETICULUM; GENE MUTATION; GENETIC DISORDER; HUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN TRANSPORT; ANIMAL; ENDOCRINE DISEASE; GENETICS; METABOLIC DISORDER; METABOLISM; MUTATION; PROTEIN CONFORMATION; REVIEW;

ANIMALS; ENDOCRINE SYSTEM DISEASES; ENDOPLASMIC RETICULUM; HUMANS; METABOLIC DISEASES; MUTATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED;

EID: 16644366865     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.08.001     Document Type: Review

References (31)

1. R.R. Kopito D. Ron Conformational disease Nat Cell Biol 2 2000 E207-E209
2. R.W. Carrell D.A. Lomas Conformational disease Lancet 350 1997 134-138
3. R. Sitia I. Braakman Quality control in the endoplasmic reticulum protein factory Nature 426 2003 891-894
4. D.J. Selkoe Folding proteins in fatal ways Nature 426 2003 900-904
5. V. Bernier M. Lagace D.G. Bichet M. Bouvier Pharmacological chaperones: potential treatment for conformational diseases Trends Endocrinol Metab 15 2004 222-228
6. P.M. Conn A. Leanos-Miranda J.A. Janovick Protein origami: Therapeutics rescue of misfolded gene products Molecular Interventions 2 2002 308-316
7. D.H. Perlmutter Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking Pediatr Res 52 2002 832-836
8. J.P. Morello D.G. Bichet Nephrogenic diabetes insipidus Annu Rev Physiol 63 2001 607-630
9. Y. Ala D. Morin B. Mouillac N. Sabatier R. Vargas Cotte M. Dechaux C. Antignac M.F. Arthus M. Lonergan Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype J Am Soc Nephrol 9 1998 1861-1872
10. H.M. Sadeghi G. Innamorati M. Birnbaumer An X-linked NDI mutation reveals a requirement for cell surface V2R expression Mol Endocrinol 11 1997 706-713
11. H. Tsukaguchi H. Matsubara S. Taketani Y. Mori T. Seido M. Inada Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus J Clin Invest 96 1995 2043-2050
12. T. Schoneberg J. Yun D. Wenkert J. Wess Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide EMBO J 15 1996 1283-1291
13. A. Oksche R. Schulein C. Rutz U. Liebenhoff J. Dickson H. Muller M. Birnbaumer W. Rosenthal Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: Analysis of expression, processing, and function Mol Pharmacol 50 1996 820-828
14. C.R. Brown L.Q. Hong-Brown J. Biwersi A.S. Verkman W.J. Welch Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein Cell Stress Chaperones 1 1996 117-125
15. S. Sato C.L. Ward M.E. Krouse J.J. Wine R.R. Kopito Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation J Biol Chem 271 1996 635-638
16. J.P. Morello A. Salahpour A. Laperriere V. Bernier M.F. Arthus M. Lonergan U. Petaja-Repo S. Angers D. Morin D.G. Bichet M. Bouvier Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants J Clin Invest 105 2000 887-895
17. V. Bernier M. Lagace M. Lonergan M.F. Arthus D.G. Bichet M. Bouvier Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059 Mol Endocrinol 18 2004 2074-2084
18. U.E. Petaja-Repo M. Hogue S. Bhalla A. Laperriere J.P. Morello M. Bouvier Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation EMBO J 21 2002 1628-1637
19. J.P. Morello A. Salahpour U.E. Petaja-Repo A. Laperriere M. Lonergan M.F. Arthus I.R. Nabi D.G. Bichet M. Bouvier Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus Biochemistry 40 2001 6766-6775
20. A. Ulloa-Aguirre J.A. Janovick A. Leanos-Miranda P.M. Conn Misrouted cell surface receptors as a novel disease aetiology and potential therapeutic target: The case of hypogonadotropic hypogonadism due to gonadotropin-releasing hormone resistance Expert Opin Ther Targets 7 2003 175-185
21. J.A. Janovick G. Maya-Nunez P.M. Conn Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: Misrouted proteins as a novel disease etiology and therapeutic target J Clin Endocrinol Metab 87 2002 3255-3262
22. A. Leanos-Miranda J.A. Janovick P.M. Conn Receptor-misrouting: An unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism J Clin Endocrinol Metab 87 2002 4825-4828
23. M.S. Gelman R.R. Kopito Rescuing protein conformation: Prospects for pharmacological therapy in cystic fibrosis J Clin Invest 110 2002 1591-1597
24. M. Sharma F. Pampinella C. Nemes M. Benharouga J. So K. Du K.G. Bache B. Papsin N. Zerangue H. Stenmark G.L. Lukacs Misfolding diverts CFTR from recycling to degradation: Quality control at early endosomes J Cell Biol 164 2004 923-933
25. J.A. Janovick M. Goulet E. Bush J. Greer D.G. Wettlaufer P.M. Conn Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor J Pharmacol Exp Ther 305 2003 608-614
26. R.S. Saliba P.M. Munro P.J. Luthert M.E. Cheetham The cellular fate of mutant rhodopsin: Quality control, degradation and aggresome formation J Cell Sci 115 2002 2907-2918
27. M.E. Illing R.S. Rajan N.F. Bence R.R. Kopito A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system J Biol Chem 277 2002 34150-34160
28. A. Rattner H. Sun J. Nathans Molecular genetics of human retinal disease Annu Rev Genet 33 1999 89-131
29. S.M. Noorwez R. Malhotra J.H. McDowell K.A. Smith M.P. Krebs S. Kaushal Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H J Biol Chem 279 2004 16278-16284
30. S.M. Noorwez V. Kuksa Y. Imanishi L. Zhu S. Filipek K. Palczewski S. Kaushal Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa J Biol Chem 278 2003 14442-14450
31. U.E. Petaja-Repo M. Hogue A. Laperriere P. Walker M. Bouvier Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor J Biol Chem 275 2000 13727-13736